Genta
Executive Summary
Development stage company specializing in antisense oligonucleotide technology has completed a $ 6.75 mil. first round of venture capital funding. Along with $ 1.8 mil. in seed money, the the San Diego-based biopharmaceutical firm, which was organized in February, has raised $ 8.55 mil. to date.